News & Press
On Easter Sunday, April 4, 2021, CordenPharma Chenôve, near Dijon in the Côte d’Or region of France, was honored to welcome Thierry Breton, former EU Minister of Economy, Finance & Industry, now European Commissioner for Internal Markets in charge of the EU Vaccines Strategy & Steering Board against COVID-19. Mr. Breton began his visit by commenting, “France is about to switch to massive vaccine production.”
Joined by CordenPharma CEO & President Dr. Michael Quirmbach, CordenPharma Chenôve Managing Director Yves Michon, and Global Peptides, Lipids & Carbohydrates Platform Director Dr. Matthieu Giraud, the Commissioner made a point of visiting on the traditional Easter holiday to thank the scientific teams and operators at CordenPharma Chenôve for their tireless efforts working round the clock, seven days a week, as one of three CordenPharma facilities to supply critical lipid excipients for Moderna’s COVID-19 mRNA vaccine.
EU Commissioner Thierry Breton comments, “France is about to switch to massive vaccine production.”
The visit was a chance for the Commissioner to acknowledge the EU’s contributions towards global vaccine production, and mark the progress of vaccination rollout in France with the imminent opening of the region’s local version of “Vaccinodrome,” the mega vaccine center in Paris’s popular football venue Stade de France.
CordenPharma Chenôve Managing Director Yves Michon commented, “Thierry Breton’s visit meant a great deal to my team, especially on the Easter holiday, as it represented an acknowledgement of our tremendous team spirit and hard work over the last month and year. Our #future vaccine is finally almost here, and we are very proud to be a part of it.”
CEO Dr. Michael Quirmbach notes, “We thank Thierry Breton for recognizing CordenPharma Chenôve’s important contribution in our global network. It is due to their continuous efforts, along with those of all CordenPharma facilities, that we have been able to ensure business continuity in providing not only this critical lipid component for mRNA vaccines, but other lifesaving medications for our customers over the last year.”